Codexis: Peers

The FY2024 (Dec) proxy of Codexis names 18 peer companies for pay. Among Codexis and these peers, CEO pay was 5th highest of 6 and total shareholder return was 5th highest of 6.

5th highest of 6in Codexis and its pay peers, FY2024 (Dec) by CEO pay:

$1.5M$6.4M

5th highest of 6in Codexis and its pay peers, FY2024 (Dec) by total shareholder return:

$10$45

Pay peer group, FY2024 (Dec) proxy

Quanterix
Regenxbio
Quantum-Si
Seer
Personalis
AbsciNot disclosedNot disclosed
Akoya BiosciencesNot disclosedNot disclosed
Alpha TeknovaNot disclosedNot disclosed
Anika TherapeuticsNot disclosedNot disclosed
Avid BioservicesNot disclosedNot disclosed
Bionano GenomicsNot disclosedNot disclosed
Harvard BiosciencesNot disclosedNot disclosed
MaxcyteNot disclosedNot disclosed
NanoString TechnologiesNot disclosedNot disclosed
Rapid Micro BiosystemsNot disclosedNot disclosed
Sangamo TherapeuticsNot disclosedNot disclosed
SomaLogicNot disclosedNot disclosed
Standards BioToolsNot disclosedNot disclosed
18 companies

Changes by year

FY2024 (Dec) proxy

  • RemovedAmyrispay peer groupIn addition, Amyris, Atrion, Berkeley Lights, BioCryst Pharmaceuticals, Deciphera Pharmaceuticals, Editas Medicine, Heron Therapeutics, ImmunoGen, MacroGenics, Precigen, and Seres Therapeutics were removed as either they have a biotherapeutic focus or they were no longer viewed as comparable to the Company based on the criteria above
  • RemovedAtrionpay peer groupIn addition, Amyris, Atrion, Berkeley Lights, BioCryst Pharmaceuticals, Deciphera Pharmaceuticals, Editas Medicine, Heron Therapeutics, ImmunoGen, MacroGenics, Precigen, and Seres Therapeutics were removed as either they have a biotherapeutic focus or they were no longer viewed as comparable to the Company based on the criteria above
  • RemovedBerkeley Lightspay peer groupIn addition, Amyris, Atrion, Berkeley Lights, BioCryst Pharmaceuticals, Deciphera Pharmaceuticals, Editas Medicine, Heron Therapeutics, ImmunoGen, MacroGenics, Precigen, and Seres Therapeutics were removed as either they have a biotherapeutic focus or they were no longer viewed as comparable to the Company based on the criteria above
  • RemovedBiocryst Pharmaceuticalspay peer groupIn addition, Amyris, Atrion, Berkeley Lights, BioCryst Pharmaceuticals, Deciphera Pharmaceuticals, Editas Medicine, Heron Therapeutics, ImmunoGen, MacroGenics, Precigen, and Seres Therapeutics were removed as either they have a biotherapeutic focus or they were no longer viewed as comparable to the Company based on the criteria above
  • RemovedDeciphera Pharmaceuticalspay peer groupIn addition, Amyris, Atrion, Berkeley Lights, BioCryst Pharmaceuticals, Deciphera Pharmaceuticals, Editas Medicine, Heron Therapeutics, ImmunoGen, MacroGenics, Precigen, and Seres Therapeutics were removed as either they have a biotherapeutic focus or they were no longer viewed as comparable to the Company based on the criteria above
  • RemovedEditas Medicinepay peer groupIn addition, Amyris, Atrion, Berkeley Lights, BioCryst Pharmaceuticals, Deciphera Pharmaceuticals, Editas Medicine, Heron Therapeutics, ImmunoGen, MacroGenics, Precigen, and Seres Therapeutics were removed as either they have a biotherapeutic focus or they were no longer viewed as comparable to the Company based on the criteria above
  • RemovedHeron Therapeuticspay peer groupIn addition, Amyris, Atrion, Berkeley Lights, BioCryst Pharmaceuticals, Deciphera Pharmaceuticals, Editas Medicine, Heron Therapeutics, ImmunoGen, MacroGenics, Precigen, and Seres Therapeutics were removed as either they have a biotherapeutic focus or they were no longer viewed as comparable to the Company based on the criteria above
  • RemovedImmunoGenpay peer groupIn addition, Amyris, Atrion, Berkeley Lights, BioCryst Pharmaceuticals, Deciphera Pharmaceuticals, Editas Medicine, Heron Therapeutics, ImmunoGen, MacroGenics, Precigen, and Seres Therapeutics were removed as either they have a biotherapeutic focus or they were no longer viewed as comparable to the Company based on the criteria above
  • RemovedMacroGenicspay peer groupIn addition, Amyris, Atrion, Berkeley Lights, BioCryst Pharmaceuticals, Deciphera Pharmaceuticals, Editas Medicine, Heron Therapeutics, ImmunoGen, MacroGenics, Precigen, and Seres Therapeutics were removed as either they have a biotherapeutic focus or they were no longer viewed as comparable to the Company based on the criteria above
  • RemovedPrecigenpay peer groupIn addition, Amyris, Atrion, Berkeley Lights, BioCryst Pharmaceuticals, Deciphera Pharmaceuticals, Editas Medicine, Heron Therapeutics, ImmunoGen, MacroGenics, Precigen, and Seres Therapeutics were removed as either they have a biotherapeutic focus or they were no longer viewed as comparable to the Company based on the criteria above
  • RemovedSeres Therapeuticspay peer groupIn addition, Amyris, Atrion, Berkeley Lights, BioCryst Pharmaceuticals, Deciphera Pharmaceuticals, Editas Medicine, Heron Therapeutics, ImmunoGen, MacroGenics, Precigen, and Seres Therapeutics were removed as either they have a biotherapeutic focus or they were no longer viewed as comparable to the Company based on the criteria above

FY2023 (Dec) proxy

  • RemovedCytokineticspay peer groupdue to its acquisition
  • RemovedInovio Pharmaceuticalspay peer groupdue to its acquisition
  • RemovedMeridian Biosciencepay peer groupdue to its acquisition

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.